Volume 67, Issue 5, Supplement , Pages 44-52, May 2009
Intravenous Bisphosphonate Therapy and Bisphosphonate-Related Osteonecrosis of the Jaws
The purposes of this report are to 1) summarize the epidemiologic evidence supporting an association between intravenous bisphosphonate (BP) exposure and BP-related osteonecrosis of the jaws (BRONJ), 2) identify measurable risk factors associated with BRONJ, and 3) assess the risk of BRONJ for patients receiving intravenous BPs to manage osteoporosis. The results of this review suggest a compelling, circumstantial association between intravenous BP exposure and BRONJ. The factors consistently associated with an increased risk of BRONJ included intravenous BP exposure in the setting of malignancy and dentoalveolar procedures. Finally, intravenous BP therapy for osteoporosis does not measurably increase the risk of BRONJ among postmenopausal women.
To access this article, please choose from the options below
Preparation of this manuscript was supported by the Massachusetts General Hospital, Department of Oral and Maxillofacial Surgery's Center for Applied Clinical Investigation and Education and Research Fund and Massachusetts General Physicians Organization.
PII: S0278-2391(08)01830-2
doi:10.1016/j.joms.2008.12.004
© 2009 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
Volume 67, Issue 5, Supplement , Pages 44-52, May 2009
